Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Oct;66(4):744–747. doi: 10.1038/bjc.1992.350

Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women.

A L Jones 1, T J Powles 1, J G Treleaven 1, J F Burman 1, M C Nicolson 1, H I Chung 1, S E Ashley 1
PMCID: PMC1977438  PMID: 1419616

Abstract

Tamoxifen has been implicated as a risk factor for venous thrombosis in advanced breast cancer although the evidence for increased arterial or venous thrombosis with tamoxifen in early breast cancer is less clear. The effect of tamoxifen on haemostasis, and thereby possible thromboembolic risk, was investigated in normal women enrolled in a placebo controlled trial of tamoxifen as a chemopreventative agent for breast cancer. There was an initial reduction in fibrinogen levels in all women on tamoxifen over the first year of follow-up and a marginal reduction in antithrombin III and Protein S in postmenopausal women at 6 months. There were no changes in cross linked fibrinogen degradation products or Protein C for pre or post-menopausal women. There was no increase in the incidence of thromboembolic events on tamoxifen. This study demonstrates that tamoxifen has only marginal effects on factors involved in haemostasis reported to affect the incidence of arterial or venous thromboembolic disease. The follow-up time is relatively short (maximum 36 months) and careful long term follow-up is necessary to detect clinically significant morbidity.

Full text

PDF
744

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Avrameas S., Ternynck T. Peroxidase labelled antibody and Fab conjugates with enhanced intracellular penetration. Immunochemistry. 1971 Dec;8(12):1175–1179. doi: 10.1016/0019-2791(71)90395-8. [DOI] [PubMed] [Google Scholar]
  2. Becker U., Bartl K., Wahlefeld A. W. A functional photometric assay for plasma fibrinogen. Thromb Res. 1984 Sep 1;35(5):475–484. doi: 10.1016/0049-3848(84)90280-9. [DOI] [PubMed] [Google Scholar]
  3. Boschetti C., Cortellaro M., Nencioni T., Bertolli V., Della Volpe A., Zanussi C. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women. Thromb Res. 1991 Apr;62(1-2):1–8. doi: 10.1016/0049-3848(91)90663-h. [DOI] [PubMed] [Google Scholar]
  4. Cook N. S., Ubben D. Fibrinogen as a major risk factor in cardiovascular disease. Trends Pharmacol Sci. 1990 Nov;11(11):444–451. doi: 10.1016/0165-6147(90)90125-r. [DOI] [PubMed] [Google Scholar]
  5. Dahan R., Espie M., Mignot L., Houlbert D., Chanu B. Tamoxifen and arterial thrombosis. Lancet. 1985 Mar 16;1(8429):638–638. doi: 10.1016/s0140-6736(85)92173-7. [DOI] [PubMed] [Google Scholar]
  6. Esmon C. T. The regulation of natural anticoagulant pathways. Science. 1987 Mar 13;235(4794):1348–1352. doi: 10.1126/science.3029867. [DOI] [PubMed] [Google Scholar]
  7. Fex G., Adielsson G., Mattson W. Oestrogen-like effects of tamoxifen on the concentration of proteins in plasma. Acta Endocrinol (Copenh) 1981 May;97(1):109–113. doi: 10.1530/acta.0.0970109. [DOI] [PubMed] [Google Scholar]
  8. Fornander T., Rutqvist L. E., Cedermark B., Glas U., Mattsson A., Skoog L., Somell A., Theve T., Wilking N., Askergren J. Adjuvant tamoxifen in early-stage breast cancer: effects on intercurrent morbidity and mortality. J Clin Oncol. 1991 Oct;9(10):1740–1748. doi: 10.1200/JCO.1991.9.10.1740. [DOI] [PubMed] [Google Scholar]
  9. Heijboer H., Brandjes D. P., Büller H. R., Sturk A., ten Cate J. W. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med. 1990 Nov 29;323(22):1512–1516. doi: 10.1056/NEJM199011293232202. [DOI] [PubMed] [Google Scholar]
  10. Hendrick A., Subramanian V. P. Tamoxifen and thromboembolism. JAMA. 1980 Feb 8;243(6):514–515. [PubMed] [Google Scholar]
  11. Hesse R., Tritschler W., Castelfranchi G., Bablok W. Antithrombin III: Referenzwerte mit einem chromogenen Substrat (Chromozym TH). Blut. 1981 Apr;42(4):227–234. doi: 10.1007/BF00996752. [DOI] [PubMed] [Google Scholar]
  12. Jordan V. C., Fritz N. F., Tormey D. C. Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. Cancer Res. 1987 Aug 15;47(16):4517–4519. [PubMed] [Google Scholar]
  13. Lane D. A., Preston F. E., VanRoss M. E., Kakkar V. V. Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation. Br J Haematol. 1978 Dec;40(4):609–615. doi: 10.1111/j.1365-2141.1978.tb05837.x. [DOI] [PubMed] [Google Scholar]
  14. Langan-Fahey S. M., Tormey D. C., Jordan V. C. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer. 1990;26(8):883–888. doi: 10.1016/0277-5379(90)90191-u. [DOI] [PubMed] [Google Scholar]
  15. Lipton A., Harvey H. A., Hamilton R. W. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep. 1984 Jun;68(6):887–889. [PubMed] [Google Scholar]
  16. Lowe G. D., Wood D. A., Douglas J. T., Riemersma R. A., Macintyre C. C., Takase T., Tuddenham E. G., Forbes C. D., Elton R. A., Oliver M. F. Relationships of plasma viscosity, coagulation and fibrinolysis to coronary risk factors and angina. Thromb Haemost. 1991 Apr 8;65(4):339–343. [PubMed] [Google Scholar]
  17. Nevasaari K., Heikkinen M., Taskinen P. J. Tamoxifen and thrombosis. Lancet. 1978 Oct 28;2(8096):946–947. doi: 10.1016/s0140-6736(78)91668-9. [DOI] [PubMed] [Google Scholar]
  18. Powles T. J., Hardy J. R., Ashley S. E., Farrington G. M., Cosgrove D., Davey J. B., Dowsett M., McKinna J. A., Nash A. G., Sinnett H. D. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer. 1989 Jul;60(1):126–131. doi: 10.1038/bjc.1989.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Powles T. J., Tillyer C. R., Jones A. L., Ashley S. E., Treleaven J., Davey J. B., McKinna J. A. Prevention of breast cancer with tamoxifen--an update on the Royal Marsden Hospital pilot programme. Eur J Cancer. 1990;26(6):680–684. doi: 10.1016/0277-5379(90)90116-b. [DOI] [PubMed] [Google Scholar]
  20. Robinson G. E., Burren T., Mackie I. J., Bounds W., Walshe K., Faint R., Guillebaud J., Machin S. J. Changes in haemostasis after stopping the combined contraceptive pill: implications for major surgery. BMJ. 1991 Feb 2;302(6771):269–271. doi: 10.1136/bmj.302.6771.269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Rylatt D. B., Blake A. S., Cottis L. E., Massingham D. A., Fletcher W. A., Masci P. P., Whitaker A. N., Elms M., Bunce I., Webber A. J. An immunoassay for human D dimer using monoclonal antibodies. Thromb Res. 1983 Sep 15;31(6):767–778. doi: 10.1016/0049-3848(83)90108-1. [DOI] [PubMed] [Google Scholar]
  22. Saphner T., Tormey D. C., Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991 Feb;9(2):286–294. doi: 10.1200/JCO.1991.9.2.286. [DOI] [PubMed] [Google Scholar]
  23. Sporrong T., Mattsson L. A., Samsioe G., Stigendal L., Hellgren M. Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. Br J Obstet Gynaecol. 1990 Oct;97(10):939–944. doi: 10.1111/j.1471-0528.1990.tb02451.x. [DOI] [PubMed] [Google Scholar]
  24. Stout R. W., Crawford V. Seasonal variations in fibrinogen concentrations among elderly people. Lancet. 1991 Jul 6;338(8758):9–13. doi: 10.1016/0140-6736(91)90004-9. [DOI] [PubMed] [Google Scholar]
  25. Tabernero M. D., Tomas J. F., Alberca I., Orfao A., Lopez Borrasca A., Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol. 1991 Apr;36(4):249–254. doi: 10.1002/ajh.2830360405. [DOI] [PubMed] [Google Scholar]
  26. Wiesel M. L., Borg J. Y., Grunebaum L., Vasse M., Levesque H., Bierme R., Sie P. Influence du déficit constitutionnel en protéine S sur le risque thrombotique artériel. Presse Med. 1991 Jun 8;20(22):1023–1027. [PubMed] [Google Scholar]
  27. Woodhams B. J. The simultaneous measurement of total and free protein S by ELISA. Thromb Res. 1988 Apr 1;50(1):213–220. doi: 10.1016/0049-3848(88)90189-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES